Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
24 May 2024 - 9:45PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2024
Commission file number: 001-41598
YS BIOPHARMA CO., LTD.
(Exact name of registrant as specified in its charter)
Building No. 2, 38 Yongda Road
Daxing Biomedical Industry Park
Daxing District, Beijing, PRC
Tel: 010-89202086
(Address of Principal Executive Offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form
40-F ☐
EXHIBITS
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
YS Biopharma Co., Ltd. |
|
|
|
By: |
/s/ Hui Shao |
|
Name: |
Hui Shao |
|
Title: |
Director and Co-Chief Executive Officer |
Date: May 24, 2024
Exhibit 99.1
YS Biopharma Announces Name Change to LakeShore
Biopharma
GAITHERSBURG, Md., May 24, 2024 /PRNewswire/ --
YS Biopharma Co., Ltd. (Nasdaq: YS) (“YS Biopharma” or the “Company”), a global biopharmaceutical company dedicated
to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases
and cancer, today announced it is changing its legal name from “YS Biopharma Co., Ltd.” to “LakeShore Biopharma Co.,
Ltd”.
Dr. David Shao, Director, President, Co-Chief
Executive Officer, and Chief Business Officer of the Company, commented, “We have decided to change our company name to LakeShore
Biopharma to align with our global market positioning and international brand image. This change marks one of the first steps for us to
expand our market reach, and we are eager to move forward and drive success under our new company name.”
The name change and trading symbol change will
not affect any rights of shareholders or the Company’s operations and financial position. The Company’s ordinary shares and
warrants will continue to be listed on the Nasdaq. Effective with the opening of the trading day on May 28, 2024, the ticker symbol of
the Company’s ordinary shares and warrants will change from “YS” to “LSB” and from “YSBPW” to
“LSBPW”, respectively. There is no action required by the Company’s current shareholders with respect to the company
name or ticker symbol changes. The Company’s CUSIP will not change in connection with the name change.
About LakeShore Biopharma (formerly known as YS Biopharma)
LakeShore Biopharma, previously known as YS Biopharma, is
a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and
therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform
and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other
virus infections. The Company operates in China, the United States, Singapore, and the Philippines, and is led by a management team that
combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.ysbiopharma.com.
Investor Relations Contact
Alyssa Li
Director of Investor Relations
Email: ir@yishengbio.com
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com
YS Biopharma (NASDAQ:YSBPW)
Historical Stock Chart
From Aug 2024 to Sep 2024
YS Biopharma (NASDAQ:YSBPW)
Historical Stock Chart
From Sep 2023 to Sep 2024